NC
EGRX

NewSquare Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

NewSquare Capital’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-150
Closed -$6K – 410
2016
Q1 		$6K Buy
+150
New +$9.52K ﹤0.01% 342

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

NewSquare Capital's EGRX Position: Q2 2016 in Review

NewSquare Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2016, closing a stake of 150 shares — an estimated $6K sold.

NewSquare Capital first reported a position in EGRX in Q1 2016 and held it in 1 quarter. The position peaked at $6K in Q1 2016. 116 funds tracked by Wall St. Rank hold EGRX as of Q2 2016.

  • NewSquare Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • NewSquare Capital sold 150 Eagle Pharmaceuticals, Inc. shares in Q2 2016, an estimated $6K.
  • NewSquare Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2016 and held it in 1 quarter.
  • NewSquare Capital's Eagle Pharmaceuticals, Inc. position peaked at $6K in Q1 2016.
  • 116 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2016.

Based on NewSquare Capital's 13F filing for Q2 2016, filed 25 Jul 2016.